Reply announcement on regulatory inquiry letter regarding information disclosure in the 2023 annual report by Jiangsu YAHONG Medical Technology Co., Ltd.
Notice of Holding the 2023 Annual Shareholders Meeting of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Announcement on Changing Signed Registered Accountants by Jiangsu Aohong Pharmaceutical Technology Co., Ltd.
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on acceptance of the listing application for APL-1702 (Hexyl Hydrochloride Ointment Photodynamic Therapy System)
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on increasing the scope of business and revising the “Articles of Association” and some internal management systems of the company
Constitution of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. (revised in April 2024)
Special Report on the 2023 Non-operating Capital Occupation and Other Related Capital Transactions of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2023 Internal Control Evaluation Report
Report on the performance of the Audit Committee of the Board of Directors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. in 2023
Report of the Audit Committee of the Board of Directors of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the performance of supervisory duties by Lixin Certified Public Accountants (Special General Partnership) in 2023
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 “Improve Quality, Increase Efficiency and Value Return” Action Plan
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on publishing APL-1706 clinical trial data for bladder cancer diagnosis at the 39th European Urological Association Annual Meeting (EAU) in 2024
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on completing the industrial and commercial registration of the change in the company's business scope and issuing a business license
Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Legal Opinion of Beijing Jiayuan Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed an announcement on the release of APL-1702 international multi-center phase III clinical trial data for treating high-grade cervical squamous intraepithelial lesion at the 2024 EUROGI
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 First Extraordinary General Meeting of Shareholders Meeting Data
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on changing the company's business scope and revising the “Articles of Association”
“Constitution of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.” (revised in March 2024)
Notice of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on convening the first extraordinary general meeting of shareholders in 2024
No Data